Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29602355 | 1.00 | HMGCR (0.35) | HMGCRAAK1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL28676314 | 1.00 | HMGCR (0.35) | HMGCRAAK1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL29601942 | 0.87 | PTGDR2 (0.33) | AAK1 | |
| SCHEMBL22823753 | 0.87 | PTGDR2 (0.33) | AAK1 | |
| SCHEMBL22823744 | 0.85 | HMGCR (0.30) | HMGCR | |
| SCHEMBL28678912 | 0.85 | HMGCR (0.30) | HMGCR | |
| SCHEMBL29601805 | 0.85 | HMGCR (0.30) | HMGCR | |
| SCHEMBL22823977 | 0.85 | HMGCR (0.35) | HMGCRALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL29602464 | 0.85 | HMGCR (0.35) | HMGCRALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL28678911 | 0.85 | HMGCR (0.35) | HMGCRALDH1A1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114008012-B | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-3986852-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| CN-114008012-A | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2020254559-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2020-12-24 | — | — | WO | disclosed |